Mr Hashim Ahmed

Mr Hashim AhmedTel: 020 3447 9194
Fax: 020 3447 9303
Email: hashim.ahmed@ucl.ac.uk

Location:
University College Hospital; National Hospital for Neurology and Neurosurgery

Specialities:
Urological Cancers, Prostate Cancer, Urology

Professional background

Hashim Uddin Ahmed
FRCS(Urol), PhD, BM, BCh (Oxon), BA(Hons)

MRC Clinician Scientist and Honorary Consultant Urological Surgeon

Hashim qualified from the University of Oxford where he attended St Peters College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospitals Manchester before returning to Oxford for an Anatomy Prosector post. Hashim then held senior house jobs in surgery on the Royal Free Hospital, London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital/Imperial College, University College Hospital and Watford General Hospital as part of the Imperial College Urology Rotation.

He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, photodynamic therapy, cryotherapy and radiofrequency ablation. He has completed numerous phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is lead PI and Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up. He currently holds a £1.2M MRC Clinician Scientist Fellowship for 5 years.

He has been visiting professor to UCLA, Tokyo and Weill-Cornell universities and has given over 30 plenary lectures at national and international urology, oncology and imaging meetings.

He holds a number of committee positions:
- Urology Editor, Cochrane Renal Group
- Member, Prostate Clinical Studies Group, NCRI
- Member, Screening, Prevention, Early Diagnosis (SPED) group, NCRI
- Consulting Editor in Imaging, British Journal of Urology International
- Editorial Board, European Urology journal
- Scientific Director, UCL Clinical Trials Group (Surgery and Interventional Trials Unit at UCL CTU)

At any one point in the minimally invasive prostate intervention group there are numerous trials recruiting to which men may be invited to join and can ask their GP or local consultant for referral to UCH.

Research interests

  • Prostate Diagnosis using novel imaging and tissue biomarkers
  • Prostate treatments that reduce the harms of traditional surgery and radiotherapy
  • Clinical trials and health technology evaluation

Publications

Summary at http://scholar.google.co.uk/citations?user=xVnw-_MAAAAJ&hl=en

Key papers
- Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361(17):1704-6.
- Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622-32.
- Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012 Nov;13(11):e509-17.  doi: 10.1016/S1470-2045(12)70388-1.
- Wilt T, Ahmed HU. Screening and treatment of localised prostate cancer. Clinical Review. BMJ (in print, due 2/2/13)

Original Articles
- Valerio M*, Ahmed HU*, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. Eur Urol. 2013 Jun 6. doi:pii: S0302-2838(13)00557-5. 10.1016/j.eururo.2013.05.048. [Epub ahead of print]
- Abd-Alazeez M, Ahmed HU, Arya M, Charman SC, Anastasiadis E, Freeman A, Emberton M, Kirkham A. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level-Can it rule out clinically significant prostate cancer? Urol Oncol. 2013 Sep 18. doi:pii: S1078-1439(13)00256-1. 10.1016/j.urolonc.2013.06.007. [Epub ahead of print]
- Abd-Alazeez M, Kirkham A, Ahmed HU, Arya M, Anastasiadis E, Charman SC, Freeman A, Emberton M. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer. Prostatic Dis. 2013 Oct 15.
- Dickinson L, Hu Y, Ahmed HU, Allen C, Kirkham AP, Emberton M, Barratt D. Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. BJU Int. 2013 Sep;112(5):594-601.
- Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. Systematic Review of Complications of Prostate Biopsy. Eur Urol. 2013 Jun 4. doi:pii: S0302-2838(13)00558-7. 10.1016/j.eururo.2013.05.049. [Epub ahead of print]
- Dickinson L, Ahmed HU, Kirkham AP, Allen C, Freeman A, Barber J, Hindley RG, Leslie T, Ogden C, Persad R, Winkler MH, Emberton M; INDEX Study Group. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. Contemp Clin Trials. 2013 Sep;36(1):68-80.
- Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Raj Persad ChM, van der Meulen J, Villers A, Emberton M; PREDICT Consensus Panel. Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol. 2013;31(3):281-4.
- Arumainayagam N*, Ahmed HU*, Moore CM, Freeman A, Allen C, Sohaib SA, Kirkham A, van der Meulen J, Emberton M. Multiparametric MR Imaging for Detection of Clinically Significant Prostate Cancer: A Validation Cohort Study with Transperineal Template Prostate Mapping as the Reference Standard. Radiology. 2013 Apr 5. [Epub ahead of print]
- Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J, Emberton M. Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer. J Urol. 2012 Oct 11. doi:pii: S0022-5347(12)05188-9. 10.1016/j.juro.2012.10.009. [Epub ahead of print]
- Robertson NL, Hu Y, Ahmed HU, Freeman A, Barratt D, Emberton M. Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study. Eur Urol. 2013 Jan 3. doi:pii: S0302-2838(12)01587-4. 10.1016/j.eururo.2012.12.057. [Epub ahead of print]
- Ahmed HU, Cathcart P, McCartan N, Kirkham A, Allen C, Freeman A, Emberton M. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: A pilot study. Cancer. 2012 Sep 1;118(17):4148-55. doi: 10.1002/cncr.27394.
- Ahmed HU, Cathcart P, Chalasani V, Williams A, McCartan N, Freeman A, Kirkham A, Allen C, Chin J, Emberton M. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer. 2012 Jun 15;118(12):3071-8. doi: 10.1002/cncr.26631.
- Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13(6):622-32.
- Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy. Ther Adv Urol. 2012 Aug;4(4):155-60.
- Karavitakis M*, Ahmed HU*, Abel PD, Livni N, Hazell S, Winkler MH. Trends in pathologic outcomes after introduction of active surveillance in the UK: Implication for focal therapy. Prostate. 2012 Feb 10. doi: 10.1002/pros.22498. [Epub ahead of print]
- Hu Y*, Ahmed HU*, Carter T, Arumainayagam N, Lecornet E, Barzell W, Freeman A, Nevoux P, Hawkes DJ, Villers A, Emberton M, Barratt DC. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int. 2012 Mar 6. doi: 10.1111/j.1464-410X.2012.10933.x. [Epub ahead of print]
- Barzell WE, Melamed MR, Cathcart P, Moore CM, Ahmed HU, Emberton M. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol. 2012 Sep;188(3):762-8.
- Lecornet E, Ahmed HU, Hu Y, Moore CM, Nevoux P, Barratt D, Hawkes D, Villers A, Emberton M. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol. 2012 Sep;188(3):974-80.
- Ahmed HU*, Hu Y*, Carter T, Arumainayagam N, Lecornet E, Hawkes D, Freeman A, Barratt D, Emberton M. Characterising Clinically Significant Prostate Cancer using Template Prostate Mapping Biopsy. J Urol. 2011;186(2):458-64.
- Ahmed HU, Freeman A, Kirkham A, Scott R, Sahu M, Allen C, van der Meulen J, Emberton M. Focal therapy in the treatment of prostate cancer – a phase I/II trial. J Urol. 2011 Apr;185(4):1246-54
- Karavitakis M*, Ahmed HU*, Abel PD, Hazell S, Winkler MH. Margin Status After Laparoscopic Radical Prostatectomy and the Index Lesion: Implications for Preoperative Evaluation of Tumor Focality in Prostate Cancer (*). J Endourol. 2012 Feb 8. [Epub ahead of print]
- Nevoux P, Ouzzane A, Ahmed HU, Emberton M, Montironi R, Presti Jr JC, Villers A. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int. 2011 Dec 22. doi: 10.1111/j.1464-410X.2011.10776.x. [Epub ahead of print]
- Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53.
- Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011 Apr;59(4):477-94
- Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010 Jun 14. [Epub ahead of print]
- Hu Y, Ahmed HU, Taylor Z, Allen C, Emberton M, Hawkes D, Barratt D. MR to ultrasound registration for image-guided prostate interventions. Med Image Anal. 2010 Dec 13. [Epub ahead of print]
- Hu Y, Ahmed HU, Allen C, Pendsé D, Sahu M, Emberton M, Hawkes D, Barratt D. MR to ultrasound image registration for guiding prostate biopsy and interventions. Med Image Comput Comput Assist Interv. 2009;12(Pt 1):787-94.
- Hu Y, van den Boom R, Carter T, Taylor Z, Hawkes D, Ahmed HU, Emberton M, Allen C, Barratt D. A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations. Prog Biophys Mol Biol. 2010 Sep 30. [Epub ahead of print]
- Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, Allen C, Kirkham A, Emberton M. Accuracy of multiparametric magnetic resonance imaging in  detecting recurrent prostate cancer after radiotherapy. BJU Int. 2010 Mar 9. [Epub ahead of print]
- Hu Y, Morgan D, Ahmed HU, Pendsé D, Sahu M, Allen C, Emberton M, Hawkes D, Barratt D. A statistical motion model based on biomechanical simulations for data fusion during image-guided prostate interventions. Med Image Comput Comput Assist Interv. 2008;11(Pt 1):737-44.
- Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer. 2009 Jul 7;101(1):19-26.
- Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2010 May 25. [Epub ahead of print]
- Ahmed HU, Ishaq A, Zacharakis E, Shaw G, Illing R, Allen C, Kirkham A, Emberton M. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2009 Feb;103(3):321-3.
- Ahmed HU, Smith JB, Rudderow DJ, Longo WE, Virgo KS,  Johnson FE. Cholecystectomy in patients with previous spinal cord injury.  American Journal of Surgery. 184 (2002): 452-459.
- Ahmed HU, Kellett C, Ashworth M, Nazir S. First Aid and CPR training for medical students in the UK. Med Educ. 2004;38(8):913.
- Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008 102(7):786-92.
- Ravichandran S, Ahmed HU, Matanhelia SS, Dobson M. Is there a role for magnetic resonance imaging in diagnosing colovesical fistulas? Urology. 2008 Oct;72(4):832-7.

Hypothesis
- Kanthabalan A, Arya M, Punwani S, Freeman A, Haroon A, Bomanji J, Emberton M,  Ahmed HU. Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer. World J Urol. 2013 Oct 13. [Epub ahead of print]
- Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 2012 Nov;13(11):e509-17.  doi: 10.1016/S1470-2045(12)70388-1.
- Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361(17):1704-6.
- Ahmed HU, Illing RO, Kirkham A, Pendse D, Allen C, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Rev Clin Oncol. 2007;4(11):632-42.
- Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, Emberton M. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol. 2009 Apr;6(4):197-206.

Editorials and Commentaries
- Ahmed HU. Editorial comment. J Urol. 2013 Oct;190(4):1232. doi:10.1016/j.juro.2013.03.143. Epub 2013 Jul 26.
- Ahmed HU. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int. 2013;111(7):1011-3. doi: 10.1111/j.1464-410X.2012.11786.x.
- Ahmed HU. Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol. 2012 Nov 13;10(1):6-8. doi: 10.1038/nrurol.2012.213.
- Ahmed HU. Focal therapy will become a standard of care in prostate cancer – Pro. J Urol. 12;187(3):792-4.
- Ahmed HU, Emberton M, Kepner G, Kepner J. A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol. 2012 Feb 7. doi: 10.1038/nrurol.2012.3. [Epub ahead of print]
- Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A on behalf of the Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. BJUI 2012 Jun;109(11):1636-47
- Ahmed HU, Emberton M. Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol. 2010;28(5):577-82.
- Lecornet E, Moore C, Ahmed HU, Emberton M. Focal therapy for prostate cancer: fact or fiction? Urol Oncol. 2010;28(5):550-6.
- Ahmed HU, Moore C, Lecornet E, Emberton M. Focal therapy in prostate cancer: determinants of success and failure. J Endourol. 2010 May;24(5):819-25.
- Ahmed HU, Emberton M. Is focal therapy the future for prostate cancer? Future Oncol. 2010;6(2):261-8.
- Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol. 2008 Oct;26(5):457-67.
- Gommersall L, Shergill IS, Ahmed HU, Arya M, Grange P, Gill IS. Nanotechnology in the management of prostate cancer. BJU Int. 2008 Dec;102(11):1493-5.
- Ahmed HU, Arya M, Mushtaq I. Comment on: Tucci S, Cologna AJ, Suaid HJ, Valera ET, Tirapelli LF, Paschoalin EL, Martins AC. Results of novel strategies for treatment of Wilms’ tumor. Int Braz J Urol. 2007;33(2):195-201; discussion 201-3
- Ahmed HU, Arya M, Minhas S. Dynamic sentinel lymph node biopsy in penile cancer. Exp Rev Anti Ther. 2006;6(7).
- Rao AR, Thwaini A, Ahmed HU, Shergill IS, Minhas S. The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary. BJU Int. 2007 Jul;100(1):3-4
- Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual basis for focal therapy in prostate cancer. J Endourol. 2010 May;24(5):811-8.
- Langley S, Ahmed HU, Al-Qaisieh B, Bostwick D, Dickinson L, Veiga FG, Grimm P, Machtens S, Guedea F, Emberton M. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int. 2012 Feb;109 Suppl 1:7-16. doi: 10.1111/j.1464-410X.2011.10825.x.

Reviews
- Kasivisvanathan V, Emberton M, Ahmed HU. Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol). 2013 Aug;25(8):461-73. doi: 10.1016/j.clon.2013.05.002.
- Karavitakis M, Winkler MH, Abel PD, Hazell S, Ahmed HU. Focal therapy for prostate cancer: opportunities and uncertainties. Discov Med. 2011;12(64):245-55.
- Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol. 2009;18(3):219-32
- Ahmed HU, Arya M, Levitt G, Duffy PG, Sebire NJ, Mushtaq I. Part II: Treatment of primary malignant non-Wilms' renal tumours in children. Lancet Oncol. 2007 Sep;8(9):842-8.
- Ahmed HU, Arya M, Levitt G, Duffy PG, Mushtaq I, Sebire NJ. Part I: Primary malignant non-Wilms' renal tumours in children. Lancet Oncol. 2007 Aug;8(8):730-7.
- Ahmed HU, Arya M, Muneer A, Mushtaq I, Sebire NJ. Testicular and paratesticular tumours in the prepubertal population. Lancet Oncol. 2010 May;11(5):476-83.
- Ahmed HU, Arya M, Tsiouris A, Sellaturay SV, Shergill IS, Duffy PG, Mushtaq I. An update on the management of Wilms' tumour. Eur J Surg Oncol.
- Ahmed HU, Thwaini A, Shergill IS, Hammadeh MY, Arya M, Kaisary AV. Greenlight prostatectomy: a challenge to the gold standard? A review of KTP photoselective vaporization of the prostate. Surg Laparosc Endosc Percutan Tech. 2007 Jun;17(3):156-63.
- Ahmed HU, Khan AA, Bafaloukas N, Shergill IS, Buchholz NP. Diagnosis and management of renal (ureteric) colic. Br J Hosp Med (Lond). 2006 Sep;67(9):465-9.
- Ahmed HU, Shergill IS, Matson M, Buchholz NP. The intravenous urogram. Br J Hosp Med (Lond). 2006;67(9):M170-2.
- Ahmed HU, Shergill IS, Arya M, Shah PJ. Management of detrusor-external sphincter dyssynergia. Nat Clin Pract Urol. 2006 Jul;3(7):368-80.
- Ahmed HU, Ali A, Tsiouris A, Zacharakis E, Emberton M. Chronic Prostatitis – is it still an enigma? Accepted by Clinical Focus - Primary Care (2007)
- Ahmed HU, Patel HRH, Arya M. Bladder Carcinoma: Understanding advanced and metastatic disease with potential molecular therapeutic targets. Exp Rev of Anticancer Ther. 2005; 5(6): 1011-22.
- Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Raj Persad ChM, van der Meulen J, Villers A, Emberton M; PREDICT Consensus Panel. Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol. 2013;31(3):281-4.
- Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin P, Kirkham AP, Padhani AR, Persad R, Puech P, Punwani S, Sohaib A, Tombal B, Villers A, Emberton M. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: Could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging. 2012 May 7. doi: 10.1002/jmri.23689. [Epub ahead of print]
- Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol. 2011 Jan;8(1):48-55
- Arumainayagam N, Moore CM, Ahmed HU, Emberton M. Photodynamic therapy for focal ablation of the prostate. World J Urol. 2010 May 9. [Epub ahead of print]
- Govindaraju SK, Ahmed HU, Sahu M, Emberton M. Tissue characterisation in prostate cancer using a novel ultrasound approach. British Journal of Medical and Surgical Urology (2008) 1, 98—106
- Muneer A, Kayes O, Ahmed HU, Arya M, Minhas S. Molecular prognostic factors in penile cancer. World J Urol. 2008 12.
- Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol. 2007;8(5):420-9.
- Gommersall L, Shergill IS, Ahmed HU, Hayne D, Arya M, Patel HR, Hashizume M, Gill IS. Nanotechnology and its relevance to the urologist. Eur Urol. 2007 52(2):368-75.
- Tsiouris A, Ahmed HU, Kumar N, Kaisary AV. Urachal tumour: clinical and radiological features of a poorly understood carcinoma. Ann R Coll Surg Engl. 2007;89(6):W17-8.
- Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg Oncol. 2006 Nov;15(3):117-28.

Letters
- Donaldson IA, Moore CM, Emberton M, Ahmed HU. Re: Geometric Evaluation of Systematic Transrectal Ultrasound Guided Prostate Biopsy: M. Han, D. Chang, C. Kim, B. J. Lee, Y. Zuo, H.-J. Kim, D. Petrisor, B. Trock, A. W. Partin, R. Rodriguez, H. B. Carter, M. Allaf, J. Kim and D. Stoianovici J Urol 2012; 188: 2404-2409. J Urol. 2013 Feb 8. doi:pii: S0022-5347(13)00253-X.10.1016/j.juro.2013.02.001. [Epub ahead of print]
- Ahmed HU, Emberton M. Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy. BMJ. 2012 Feb 28;344:e1438. doi:10.1136/bmj.e1438.
- Ahmed HU, Emberton M. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009 Jul;104(2):269-70; author reply 270.
- Ahmed HU, Arya M, Emberton M. Irreversible tide of technological advancement? BMJ. 2008;337:a903. doi: 10.1136/bmj.a903
- Ahmed HU, Emberton M. Re: Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities. S. E. Eggener, P. T. Scardino, P. R. Carroll, M. J. Zelefsky, O. Sartor, H. Hricak, T. M. Wheeler, S. W. Fine, J. Trachtenberg, M. A. Rubin, M. Ohori, K. Kuroiwa, M. Rossignol and L. Abenhaim, International Task Force on Prostate Cancer and the Focal Lesion Paradigm J Urol 2007; 178: 2260-2267. J Urol. 2008 Jun 12.
- Ahmed HU, Calleary J, Arya M, Emberton M, Illing RO, Allen C. Re: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau, L. Lemaitre, J Urol 2006; 176: 2432-2437. J Urol. 2007 Jun;177(6):2395
- Hotston MR, Ahmed HU, Persad R. General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. BJU Int.
2012 Nov;110(9):E429; author reply E429-30. doi:
10.1111/j.1464-410X.2012.11623.x.
- Dickinson L, Ahmed HU, Emberton M. Re: salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer N. Lawrentschuk, a. Finelli, T. H. Van der kwast, p. Ryan, d. M. Bolton, N. E. Fleshner, j. Trachtenberg, L. Klotz, m. Robinette and h. Woo j urol 2011;185: 862-868. J Urol. 2011 Sep;186(3):1159-61.
- Singh PB, Ahmed HU, Simmons L, Freeman A, Emberton M. Time to Rethink PSA Screening. Arch Intern Med. 2011 Mar 28;171(6):595
- Singh PB, Ahmed HU, Emberton M. Active Surveillance: Is There a Need for Better Risk Stratification at the Outset? J Clin Oncol. 2010 Aug 9. [Epub ahead of print]
- Dickinson L, Ahmed HU, Moore C, Freeman A, Kirkham A, Allen C, Emberton M. The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int. 2010;106(1):131-2.
- Cathcart P, Ahmed HU, Moore C, Emberton M. Life after prostate cancer. Time to evaluate focal therapy. BMJ. 2010;340:c1057.
- Tsiouris A, Ahmed HU, Kaisary AV. Letter. Nanotechnology: potential applications in urology. BJUI 2006; 98(1):231-232.

GMC/GDC number: 4771696